Eton Pharmaceuticals Reports Fourth Quarter 2022 Financial Results
March 16, 2023 16:01 ET
|
Eton Pharmaceuticals
Q4 2022 revenue of $8.5 millionQ4 Product sales and royalty revenue up 220% from prior year and 9% from Q3Q4 positive net incomeManagement to hold conference call today at 4:30pm ET DEER PARK, Ill.,...
Eton Pharmaceuticals Announces Acquisition of Rare Disease Product Candidate ET-600
March 15, 2023 06:50 ET
|
Eton Pharmaceuticals
-- Product is targeting rare pediatric endocrinology condition ---- Potential for NDA submission in Q2 2024 -- DEER PARK, Ill., March 15, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or...
Eton Pharmaceuticals to Report Fourth Quarter 2022 Financial Results on Thursday, March 16, 2023
March 07, 2023 16:05 ET
|
Eton Pharmaceuticals
DEER PARK, Ill., March 07, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare...
Eton Pharmaceuticals Announces FDA Acceptance of NDA Response for Dehydrated Alcohol Injection
January 11, 2023 06:50 ET
|
Eton Pharmaceuticals
-- Product previously granted orphan drug designation for methanol poisoning ---- Application assigned a PDUFA date of June 27, 2023 -- DEER PARK, Ill., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Eton...
Eton Pharmaceuticals Reports Third Quarter 2022 Financial Results
November 10, 2022 16:05 ET
|
Eton Pharmaceuticals
Q3 2022 revenue of $3.2 million, product sales and royalty revenue up 315% from prior year and 37% from Q2 2022Strong sales growth of ALKINDI SPRINKLE® and Carglumic AcidThird commercial product,...
Eton Pharmaceuticals to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022
November 02, 2022 16:05 ET
|
Eton Pharmaceuticals
DEER PARK, Ill., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare...
Eton Pharmaceuticals to Present at the LD Micro Main Event XV Conference
October 18, 2022 06:50 ET
|
Eton Pharmaceuticals
DEER PARK, Ill., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing...
Eton Pharmaceuticals Announces Acquisition of FDA-Approved Rare Disease Product, Betaine Anhydrous for Oral Solution
September 13, 2022 09:00 ET
|
Eton Pharmaceuticals
-- Expected to be accretive to 2023 earnings -- DEER PARK, Ill., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical...
Eton Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
August 30, 2022 16:05 ET
|
Eton Pharmaceuticals
DEER PARK, Ill., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing...
Eton Pharmaceuticals Reports Second Quarter 2022 Financial Results
August 11, 2022 16:01 ET
|
Eton Pharmaceuticals
Total Q2 2022 revenue of $7.4 million, up 139% from prior yearRecently launched ALKINDI SPRINKLE® and Carglumic Acid continue to show robust growthDivestiture of hospital products division to focus on...